MAPPA Survey: Over Half of PID Patients Diagnosed After Age 18
Maastricht – October 14, 2026 -- More than half of respondents to the MAPPA patient survey received a primary immunodeficiency (PID) diagnosis after age 18, and 28% reported permanent damage at the time of diagnosis, according to preliminary findings Kedrion Biopharma and AIP APS will present at ESID 2026.
MAPPA survey expands from Italy to Portugal, Spain and Turkey
The survey was developed by AIP APS, the Italian Association for Primary Immunodeficiencies, in collaboration with Kedrion. It collects real-world data on the experiences of people living with PIDs across Europe. The expansion from Italy to Portugal, Spain and Turkey is expected to provide new evidence on patient pathways, diagnostic journeys and unmet needs.
AIP APS President Alessandro Segato said that turning patient experiences into evidence helps identify shared needs that might otherwise remain unseen, and can strengthen diagnosis, care and support at a European level.